Latest On Revance Therapeutics, Inc (RVNC):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 06:58 EST | News | Revance Therapeutics, Inc. (RVNC) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-09 17:58 EST | News | Revance Therapeutics GAAP EPS of -$0.74, revenue of $49.3M | N/A | |
| 2023-05-09 03:59 EST | News | Revance Therapeutics Q1 2023 Earnings Preview | N/A | |
| 2023-04-04 02:47 EST | News | Revance Therapeutics:Â Rally Seems Due For A Pause | N/A | |
| 2023-03-09 21:59 EST | News | Revance Therapeutics (RVNC) Investor Presentation _ Slodeshow | N/A | |
| 2023-03-01 01:00 EST | News | Revance Therapeutics GAAP EPS of -$1.82 misses by $0.78, revenue of $49.9M beats by $4.8M | N/A | |
| 2023-03-01 00:59 EST | News | Revance Therapeutics, Inc. (RVNC) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-27 19:23 EST | News | Revance Therapeutics Q4 2022 Earnings Preview | N/A | |
| 2023-01-19 22:38 EST | News | Carpe Diem, Daxxify: Revance Therapeutic Preps For An Exciting Year | N/A | |
| 2023-01-09 20:15 EST | News | Revance surges 45% as it sees revenue from RHA collection to be between $34M and $35M | N/A | |
| 2022-11-15 07:28 EST | News | Revance Therapeutics: FDA Approval Of Daxxify Only One Part Of The Journey | N/A | |
| 2022-11-09 11:51 EST | News | Revance Therapeutics, Inc. (RVNC) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-08 18:42 EST | News | Revance Therapeutics GAAP EPS of -$1.17 misses by $0.23, revenue of $29M beats by $0.76M | N/A | |
| 2022-11-08 00:20 EST | News | Revance Therapeutics Q3 2022 Earnings Preview | N/A | |
| 2022-10-20 21:40 EST | News | Revance Therapeutics submits sBLA for Daxxify for cervical dystonia | N/A | |
| 2022-10-17 19:38 EST | News | Revance appoints David Hollander, M.D as CMO | N/A | |
| 2022-09-13 17:19 EST | News | Revance Therapeutics stock slides on pricing $200.0M upsized stock offering | N/A | |
| 2022-09-12 23:36 EST | News | Revance Therapeutics plans underwritten public offering of $150M shares | N/A | |
| 2022-09-08 17:05 EST | News | Revance climbs 14% as FDA approves facial injectable for frown lines | N/A | |
| 2022-09-08 17:05 EST | News | Revance Therapeutics receives US FDA approval for DAXXIFY product | N/A | |
| 2022-09-08 17:04 EST | News | Revance nears eleven-month high as Botox rival gets FDA approval | N/A | |
| 2022-08-25 01:57 EST | News | Revance Therapeutics: More Risk To Sept. 8 PDUFA Than It Seems | N/A | |
| 2022-08-10 05:20 EST | News | Revance Therapeutics GAAP EPS of -$0.88 beats by $0.03, revenue of $28.37M beats by $0.6M | N/A | |
| 2022-08-10 05:20 EST | News | Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-09 07:36 EST | News | Revance Therapeutics Q2 2022 Earnings Preview | N/A | |
| 2022-07-15 03:12 EST | News | Revance: Potential Comeback On FDA Resubmission For DAXI | N/A | |
| 2022-05-11 09:03 EST | News | Revance Therapeutics GAAP EPS of -$0.94 beats by $0.02, revenue of $25.26M beats by $1.39M | N/A | |
| 2022-05-11 09:03 EST | News | Revance Therapeutics's (RVNC) CEO Mark Foley On Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-10 13:19 EST | News | Revance Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-22 00:40 EST | News | FDA accepts Revance's application resubmission for its injection to treat frown lines | N/A | |
| 2022-03-08 19:21 EST | News | Revance Therapeutics resubmits DaxibotulinumtoxinA BLA for frown lines | N/A | |
| 2022-03-01 12:27 EST | News | Revance Therapeutics, Inc. (RVNC) CEO Mark Foley On Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-28 18:15 EST | News | Revance Therapeutics GAAP EPS of -$0.93 beats by $0.09, revenue of $25.95M beats by $1.22M | N/A | |
| 2022-02-27 23:57 EST | News | Revance Therapeutics Q4 2021 Earnings Preview | N/A | |
| 2022-01-19 02:19 EST | News | Revance receives FDA guidance on wrinkle injection | N/A | |
| 2022-01-07 09:56 EST | News | Revance Therapeutics sees Q4 RHA Collection revenue between $23M-$24M | N/A | |
| 2021-12-07 17:22 EST | News | Revance Therapeutics rises as company insider buys share worth ~$430K | N/A | |
| 2021-12-01 08:18 EST | News | Revance Therapeutics shares 7% higher after large CEO buy | N/A | |
| 2021-11-10 15:22 EST | News | Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-09 16:25 EST | News | Revance Therapeutics EPS beats by $0.05, misses on revenue | N/A | |
| 2021-11-08 18:20 EST | News | Revance Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-29 23:56 EST | News | Revance Therapeutics: Repricing Shares After A CRL | N/A | |
| 2021-10-26 00:58 EST | News | Revance Therapeutics slips further as bearish views pile up | N/A | |
| 2021-10-21 16:28 EST | News | Warning: RVNC is at high risk of performing badly | N/A | |
| 2021-10-18 20:31 EST | News | Revance sees Street price cuts as FDA declines wrinkle injection; shares drop 41% | N/A | |
| 2021-10-15 20:14 EST | News | Revance falls 31% after FDA declines to approve wrinkle injection | N/A | |
| 2021-10-13 07:35 EST | News | Revance Therapeutics tumbles 22% following FDA inspection of facility | N/A | |
| 2021-10-13 07:34 EST | News | Revance continues to anticipate FDA approval of DaxibotulinumtoxinA for iIjection in 2021 | N/A | |
| 2021-08-16 05:16 EST | News | Revance Therapeutics: Frowning At The FDA | N/A | |
| 2021-08-08 19:31 EST | News | Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2021 Results - Earnings Call Transcript | N/A | |
About Revance Therapeutics, Inc (RVNC):
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
General
- Name Revance Therapeutics, Inc
- Symbol RVNC
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 470
- Fiscal Year EndDecember
- IPO Date2014-02-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.revance.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 102.85
- Price/Book (Most Recent Quarter) 5.07
- Enterprise Value Revenue 109.19
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$4.13
- Next Year EPS Estimate -$2.60
- Next Quarter EPS Estimate -$1.16
- Operating Margin -1684%
- Return on Assets -30%
- Return on Equity -94%
- Revenue 15.33 million
- Earnings Per Share -$3.71
- Revenue Per Share $0.26
- Gross Profit -97211000
- Quarterly Earnings Growth 12409%
View More
Highlights
- Market Capitalization 2.05 billion
- EBITDA -145464992
- PEG Ratio -0.64
- Analyst Target Price $37.8
- Book Value Per Share $5.41
View More
Share Statistics
- Shares Outstanding 71.41 million
- Shares Float 65.54 million
- % Held by Insiders 186%
- % Held by Institutions 80.37%
- Shares Short 3.43 million
- Shares Short Prior Month 3.85 million
- Short Ratio 7.04
- Short % of Float 5%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 1.24
- 52 Week High $33.64
- 52 Week Low $12.07
- 50 Day Moving Average 27.23
- 200 Day Moving Average 26.94
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Revance Therapeutics, Inc (RVNC) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Revance Therapeutics, Inc (RVNC) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-22 | $N/A | -$1.24 | -$1.26 | 1.92% |
| 2020-09-30 | 2020-11-09 | $N/A | -$1.34 | -$1.04 | -29.02% |
| 2020-06-30 | 2020-08-06 | $N/A | -$1.12 | -$1.05 | -7.18% |
| 2020-03-31 | 2020-05-07 | $N/A | -$1.15 | -$0.91 | -26.72% |
| 2019-12-31 | 2020-02-24 | $89000 | -$0.99 | -$0.97 | -2.06% |
| 2019-09-30 | 2019-11-04 | $46000 | -$0.96 | -$0.97 | 0.91% |
| 2019-06-30 | 2019-08-05 | $N/A | -$0.86 | -$0.90 | 4.44% |
| 2019-03-31 | 2019-05-08 | $278000 | -$0.85 | -$0.89 | 4.9% |
| 2018-12-31 | 2019-02-26 | $487000 | -$1.12 | -$0.93 | -20.43% |
| 2018-09-30 | 2018-11-01 | $2.36 million | -$0.91 | -$0.93 | 2.6% |
| 2018-06-30 | 2018-08-02 | $686000 | -$0.94 | -$0.91 | -3.14% |
| 2018-03-31 | 2018-05-08 | $193000 | -$0.97 | -$0.87 | -11.49% |
| 2017-12-31 | 2018-02-28 | $37000 | -$1.04 | -$0.99 | -5.84% |
| 2017-09-30 | 2017-11-02 | $75000 | -$1.01 | -$0.95 | -6.32% |
| 2017-06-30 | 2017-08-03 | $75000 | -$0.90 | -$0.95 | 5.59% |
| 2017-03-31 | 2017-05-09 | $75000 | -$0.94 | -$0.84 | -11.9% |
| 2016-12-31 | 2017-02-27 | $75000 | -$0.70 | -$0.83 | 15.88% |
| 2016-09-30 | 2016-11-03 | $75000 | -$0.64 | -$0.84 | 23.35% |
| 2016-06-30 | 2016-08-04 | $75000 | -$0.81 | -$0.86 | 6.66% |
| 2016-03-31 | 2016-05-09 | $75000 | -$0.71 | -$0.83 | 14.04% |
| 2015-12-31 | 2016-03-02 | $75000 | -$0.83 | -$0.82 | -1.84% |
| 2015-09-30 | 2015-11-09 | $75000 | -$0.81 | -$1.01 | 19.8% |
| 2015-06-30 | 2015-08-06 | $75000 | -$0.71 | -$0.84 | 15.48% |
| 2015-03-31 | 2015-05-13 | $75000 | -$0.65 | -$0.73 | 10.96% |
| 2014-12-31 | 2015-03-02 | $75000 | -$0.61 | -$0.61 | 0% |
| 2014-09-30 | 2014-11-12 | $75000 | -$0.60 | -$0.68 | 11.76% |
| 2014-06-30 | 2014-08-12 | $75000 | -$0.69 | -$0.67 | -2.99% |
| 2014-03-31 | 2014-05-13 | $158000 | -$1.81 | -$0.86 | -110.47% |
| 2013-12-31 | 2014-03-27 | $309000 | -$0.02 |
Revance Therapeutics, Inc (RVNC) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Revance Therapeutics, Inc (RVNC) Chart:
Revance Therapeutics, Inc (RVNC) News:
Below you will find a list of latest news for Revance Therapeutics, Inc (RVNC) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Revance Therapeutics, Inc (RVNC) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 1.1 | CALL | 0 | 45 | 224.99 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.06 | CALL | 100 | 1782 | 121.33 | FALSE | -0.04 | -0.4 |
| 2024-05-17 | 7.5 | 0.05 | CALL | 0 | 82 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.04 | PUT | 0 | 150 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 1.15 | PUT | 0 | 294 | 116.72 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 2.8 | PUT | 0 | 20 | 564.52 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 374.43 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | PUT | 0 | 0 | 428.4 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.95 | CALL | 0 | 31 | 305.15 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0.3 | CALL | 16 | 39 | 119.27 | FALSE | 0.05 | 0.2 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.1 | PUT | 0 | 40 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 1.4 | PUT | 0 | 7 | 103.96 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 152.7 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 1.45 | CALL | 20 | 196 | 104.85 | TRUE | 1.45 | 0 |
| 2024-07-19 | 5 | 0.3 | CALL | 7 | 1087 | 94.5 | FALSE | 0.3 | 0 |
| 2024-07-19 | 7.5 | 0.15 | CALL | 0 | 573 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 0.04 | CALL | 0 | 605 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 12.5 | 0.05 | CALL | 0 | 414 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0.12 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 17.5 | 0.05 | CALL | 0 | 15 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.25 | PUT | 0 | 810 | 117.32 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 1.6 | PUT | 10 | 330 | 112.49 | TRUE | 1.6 | 0 |
| 2024-07-19 | 7.5 | 3.84 | PUT | 0 | 213 | 113.01 | TRUE | 0 | 0 |
| 2024-07-19 | 10 | 4.95 | PUT | 0 | 59 | 159.46 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 5.25 | PUT | 0 | 0 | 342.49 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 0 | PUT | 0 | 0 | 238.17 | TRUE | 0 | 0 |
| 2024-07-19 | 17.5 | 11.75 | PUT | 0 | 0 | 353.26 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 1.71 | CALL | 0 | 132 | 266.29 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0.25 | CALL | 0 | 254 | 95.3 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.5 | CALL | 0 | 192 | 125.03 | FALSE | 0 | 0 |
| 2024-10-18 | 10 | 1.1 | CALL | 0 | 30 | 105.01 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.3 | PUT | 0 | 55 | 109.17 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 1.65 | PUT | 0 | 12 | 102.36 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 3.93 | PUT | 0 | 16 | 105.14 | TRUE | 0 | 0 |
| 2024-10-18 | 10 | 6.18 | PUT | 0 | 19 | 96.1 | TRUE | 0 | 0 |
| 2025-01-17 | 2.5 | 1.95 | CALL | 0 | 177 | 224.88 | TRUE | 0 | 0 |
| 2025-01-17 | 5 | 1.05 | CALL | 0 | 1588 | 105.24 | FALSE | 0 | 0 |
| 2025-01-17 | 7.5 | 0.5 | CALL | 34 | 2784 | 97.64 | FALSE | 0.5 | 0 |
| 2025-01-17 | 10 | 0.3 | CALL | 15 | 1540 | 97.91 | FALSE | 0.3 | 0 |
| 2025-01-17 | 12.5 | 0.25 | CALL | 0 | 416 | 105.31 | FALSE | 0 | 0 |
| 2025-01-17 | 15 | 0.17 | CALL | 0 | 729 | 101.93 | FALSE | 0 | 0 |
| 2025-01-17 | 17.5 | 0.73 | CALL | 0 | 337 | 109.53 | FALSE | 0 | 0 |
| 2025-01-17 | 20 | 0.12 | CALL | 0 | 150 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 22.5 | 0.4 | CALL | 0 | 53 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 25 | 0.12 | CALL | 0 | 351 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 30 | 0.05 | CALL | 0 | 1981 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 35 | 0.05 | CALL | 0 | 580 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 40 | 0.05 | CALL | 0 | 299 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 45 | 0.05 | CALL | 0 | 130 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 50 | 0.07 | CALL | 0 | 269 | 0 | FALSE | 0 | 0 |
| 2025-01-17 | 2.5 | 0.6 | PUT | 0 | 550 | 111.02 | FALSE | 0 | 0 |
| 2025-01-17 | 5 | 2.15 | PUT | 0 | 196 | 105.2 | TRUE | 0 | 0 |
| 2025-01-17 | 7.5 | 3.1 | PUT | 0 | 45 | 98.48 | TRUE | 0 | 0 |
| 2025-01-17 | 10 | 6.45 | PUT | 0 | 113 | 99.96 | TRUE | 0 | 0 |
| 2025-01-17 | 12.5 | 7.02 | PUT | 0 | 253 | 109.04 | TRUE | 0 | 0 |
| 2025-01-17 | 15 | 9.5 | PUT | 0 | 0 | 169.85 | TRUE | 0 | 0 |
| 2025-01-17 | 17.5 | 5 | PUT | 0 | 4 | 172.52 | TRUE | 0 | 0 |
| 2025-01-17 | 20 | 16.2 | PUT | 0 | 18 | 182.58 | TRUE | 0 | 0 |
| 2025-01-17 | 22.5 | 5.38 | PUT | 0 | 0 | 191.51 | TRUE | 0 | 0 |
| 2025-01-17 | 25 | 16.5 | PUT | 0 | 9 | 199.48 | TRUE | 0 | 0 |
| 2025-01-17 | 30 | 23 | PUT | 0 | 0 | 218.17 | TRUE | 0 | 0 |
| 2025-01-17 | 35 | 0 | PUT | 0 | 0 | 198.54 | TRUE | 0 | 0 |
| 2025-01-17 | 40 | 22.5 | PUT | 0 | 0 | 240.94 | TRUE | 0 | 0 |
| 2025-01-17 | 45 | 0 | PUT | 0 | 0 | 250.62 | TRUE | 0 | 0 |
| 2025-01-17 | 50 | 0 | PUT | 0 | 0 | 331.22 | TRUE | 0 | 0 |
Latest RVNC Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 4 | $11.54 |
| Jun 13, 2022 7:59 PM EST | 24 | $11.54 |
| Jun 13, 2022 7:59 PM EST | 57 | $11.53 |
| Jun 13, 2022 7:59 PM EST | 100 | $11.53 |
| Jun 13, 2022 7:59 PM EST | 100 | $11.53 |
Revance Therapeutics, Inc (RVNC) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000078/0001479290-20-000078-index.htm |
| 2018-09-13 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1479290/000000000018028487/0000000000-18-028487-index.htm |
| 2018-11-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1479290/000000000018034842/0000000000-18-034842-index.htm |
| 2018-12-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1479290/000000000018038280/0000000000-18-038280-index.htm |
| 2020-06-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1479290/000000000020005398/0000000000-20-005398-index.htm |
| 2020-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000001961720000115/0000019617-20-000115-index.htm |
| 2019-01-28 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000003877719000060/0000038777-19-000060-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000003877720000047/0000038777-20-000047-index.htm |
| 2019-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000021545719005714/0000215457-19-005714-index.htm |
| 2020-02-06 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000083423720006896/0000834237-20-006896-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000090221919000368/0000902219-19-000368-index.htm |
| 2020-01-08 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000090221920000050/0000902219-20-000050-index.htm |
| 2020-08-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000090221920000421/0000902219-20-000421-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000114420419006491/0001144204-19-006491-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000117266119000521/0001172661-19-000521-index.htm |
| 2019-11-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000117266119002152/0001172661-19-002152-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000117266120000901/0001172661-20-000901-index.htm |
| 2018-10-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1479290/000119312518299456/0001193125-18-299456-index.htm |
| 2018-12-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312518341645/0001193125-18-341645-index.htm |
| 2019-01-15 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1479290/000119312519009773/0001193125-19-009773-index.htm |
| 2019-01-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312519009823/0001193125-19-009823-index.htm |
| 2019-01-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1479290/000119312519010941/0001193125-19-010941-index.htm |
| 2019-01-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312519010943/0001193125-19-010943-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000119312519037708/0001193125-19-037708-index.htm |
| 2019-12-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1479290/000119312519305271/0001193125-19-305271-index.htm |
| 2019-12-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1479290/000119312519306287/0001193125-19-306287-index.htm |
| 2019-12-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312519306290/0001193125-19-306290-index.htm |
| 2020-01-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520004272/0001193125-20-004272-index.htm |
| 2020-01-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520005067/0001193125-20-005067-index.htm |
| 2020-02-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520029741/0001193125-20-029741-index.htm |
| 2020-02-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520038556/0001193125-20-038556-index.htm |
| 2020-03-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000119312520072922/0001193125-20-072922-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520145622/0001193125-20-145622-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520145623/0001193125-20-145623-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520145631/0001193125-20-145631-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146152/0001193125-20-146152-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146165/0001193125-20-146165-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146170/0001193125-20-146170-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146174/0001193125-20-146174-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146240/0001193125-20-146240-index.htm |
| 2020-05-19 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146242/0001193125-20-146242-index.htm |
| 2020-05-20 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520146486/0001193125-20-146486-index.htm |
| 2020-05-21 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520147837/0001193125-20-147837-index.htm |
| 2020-05-21 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520147859/0001193125-20-147859-index.htm |
| 2020-06-10 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520164935/0001193125-20-164935-index.htm |
| 2020-06-23 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1479290/000119312520175994/0001193125-20-175994-index.htm |
| 2020-06-23 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1479290/000119312520176001/0001193125-20-176001-index.htm |
| 2020-06-24 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1479290/000119312520177782/0001193125-20-177782-index.htm |
| 2020-07-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520197935/0001193125-20-197935-index.htm |
| 2020-07-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1479290/000119312520197940/0001193125-20-197940-index.htm |
| 2020-10-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000119312520269018/0001193125-20-269018-index.htm |
| 2020-03-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000120919120019835/0001209191-20-019835-index.htm |
| 2019-01-29 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000139077719000018/0001390777-19-000018-index.htm |
| 2019-08-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000139077719000083/0001390777-19-000083-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000098/0001479290-18-000098-index.htm |
| 2018-08-03 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000101/0001479290-18-000101-index.htm |
| 2018-10-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000103/0001479290-18-000103-index.htm |
| 2018-11-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000106/0001479290-18-000106-index.htm |
| 2018-11-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000108/0001479290-18-000108-index.htm |
| 2018-11-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000111/0001479290-18-000111-index.htm |
| 2018-11-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000112/0001479290-18-000112-index.htm |
| 2018-11-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000114/0001479290-18-000114-index.htm |
| 2018-11-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000116/0001479290-18-000116-index.htm |
| 2018-11-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000119/0001479290-18-000119-index.htm |
| 2018-11-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000121/0001479290-18-000121-index.htm |
| 2018-12-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000123/0001479290-18-000123-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000002/0001479290-19-000002-index.htm |
| 2019-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000004/0001479290-19-000004-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000006/0001479290-19-000006-index.htm |
| 2019-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000008/0001479290-19-000008-index.htm |
| 2019-01-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000010/0001479290-19-000010-index.htm |
| 2019-01-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000012/0001479290-19-000012-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000014/0001479290-19-000014-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000015/0001479290-19-000015-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000016/0001479290-19-000016-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000017/0001479290-19-000017-index.htm |
| 2019-01-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000018/0001479290-19-000018-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000020/0001479290-19-000020-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000022/0001479290-19-000022-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000024/0001479290-19-000024-index.htm |
| 2019-02-28 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000029/0001479290-19-000029-index.htm |
| 2019-02-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000030/0001479290-19-000030-index.htm |
| 2019-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000032/0001479290-19-000032-index.htm |
| 2019-03-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000034/0001479290-19-000034-index.htm |
| 2019-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000036/0001479290-19-000036-index.htm |
| 2019-03-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000038/0001479290-19-000038-index.htm |
| 2019-03-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000041/0001479290-19-000041-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000046/0001479290-19-000046-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000050/0001479290-19-000050-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000052/0001479290-19-000052-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000054/0001479290-19-000054-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000056/0001479290-19-000056-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000058/0001479290-19-000058-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000060/0001479290-19-000060-index.htm |
| 2019-05-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000062/0001479290-19-000062-index.htm |
| 2019-06-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000065/0001479290-19-000065-index.htm |
| 2019-06-06 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000067/0001479290-19-000067-index.htm |
| 2019-06-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000069/0001479290-19-000069-index.htm |
| 2019-06-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000071/0001479290-19-000071-index.htm |
| 2019-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000075/0001479290-19-000075-index.htm |
| 2019-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000076/0001479290-19-000076-index.htm |
| 2019-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000077/0001479290-19-000077-index.htm |
| 2019-07-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000079/0001479290-19-000079-index.htm |
| 2019-07-18 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000081/0001479290-19-000081-index.htm |
| 2019-07-18 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000083/0001479290-19-000083-index.htm |
| 2019-08-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000088/0001479290-19-000088-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000093/0001479290-19-000093-index.htm |
| 2019-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000098/0001479290-19-000098-index.htm |
| 2019-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000101/0001479290-19-000101-index.htm |
| 2019-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000103/0001479290-19-000103-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000108/0001479290-19-000108-index.htm |
| 2019-11-04 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000109/0001479290-19-000109-index.htm |
| 2019-12-10 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000111/0001479290-19-000111-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000113/0001479290-19-000113-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000115/0001479290-19-000115-index.htm |
| 2019-12-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000117/0001479290-19-000117-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000002/0001479290-20-000002-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000004/0001479290-20-000004-index.htm |
| 2020-01-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000006/0001479290-20-000006-index.htm |
| 2020-01-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000010/0001479290-20-000010-index.htm |
| 2020-01-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000013/0001479290-20-000013-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000015/0001479290-20-000015-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000017/0001479290-20-000017-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000019/0001479290-20-000019-index.htm |
| 2020-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000021/0001479290-20-000021-index.htm |
| 2020-02-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000024/0001479290-20-000024-index.htm |
| 2020-02-19 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000026/0001479290-20-000026-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000028/0001479290-20-000028-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000030/0001479290-20-000030-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000031/0001479290-20-000031-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000032/0001479290-20-000032-index.htm |
| 2020-02-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000033/0001479290-20-000033-index.htm |
| 2020-02-19 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000034/0001479290-20-000034-index.htm |
| 2020-02-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000038/0001479290-20-000038-index.htm |
| 2020-02-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/0001479290-20-000042-index.htm |
| 2020-03-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000048/0001479290-20-000048-index.htm |
| 2020-03-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000050/0001479290-20-000050-index.htm |
| 2020-04-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000052/0001479290-20-000052-index.htm |
| 2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000056/0001479290-20-000056-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000058/0001479290-20-000058-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000062/0001479290-20-000062-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000064/0001479290-20-000064-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000065/0001479290-20-000065-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000066/0001479290-20-000066-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000067/0001479290-20-000067-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000068/0001479290-20-000068-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000069/0001479290-20-000069-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000071/0001479290-20-000071-index.htm |
| 2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000074/0001479290-20-000074-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000076/0001479290-20-000076-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000078/0001479290-20-000078-index.htm |
| 2020-07-27 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000080/0001479290-20-000080-index.htm |
| 2020-07-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000082/0001479290-20-000082-index.htm |
| 2020-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000089/0001479290-20-000089-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000090/0001479290-20-000090-index.htm |
| 2020-10-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000093/0001479290-20-000093-index.htm |
| 2019-01-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1479290/000156761919000431/0001567619-19-000431-index.htm |
| 2018-10-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828018012608/0001628280-18-012608-index.htm |
| 2020-09-30 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014080/0001628280-20-014080-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014083/0001628280-20-014083-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014238/0001628280-20-014238-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014240/0001628280-20-014240-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014242/0001628280-20-014242-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014244/0001628280-20-014244-index.htm |
| 2020-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014246/0001628280-20-014246-index.htm |
| 2020-10-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014509/0001628280-20-014509-index.htm |
| 2020-06-24 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1479290/999999999520001527/9999999995-20-001527-index.htm |
| 2018-09-06 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1479290/999999999718007650/9999999997-18-007650-index.htm |
| 2019-03-18 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1479290/999999999719001368/9999999997-19-001368-index.htm |
| 2019-05-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1479290/999999999719004527/9999999997-19-004527-index.htm |
| 2020-02-03 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1479290/999999999720000433/9999999997-20-000433-index.htm |
| 2020-02-07 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1479290/999999999720000597/9999999997-20-000597-index.htm |
| 2020-02-27 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1479290/999999999720001053/9999999997-20-001053-index.htm |
Revance Therapeutics, Inc (RVNC) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Revance Therapeutics, Inc (RVNC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 186%Institutional Ownership: 8037%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-05-09 | Angus C. Russell | Director | Buy | 4,500.00 | 10,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000060/0001479290-19-000060-index.htm | ||
| 2019-05-09 | Julian S Gangolli | Director | Buy | 4,500.00 | 10,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000056/0001479290-19-000056-index.htm | ||
| 2019-05-09 | PHYLLIS GARDNER | Director | Buy | 4,500.00 | 10,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000058/0001479290-19-000058-index.htm | ||
| 2019-05-09 | ROBERT F BYRNES | Director | Buy | 4,500.00 | 10,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000052/0001479290-19-000052-index.htm | ||
| 2020-01-23 | Abhay Joshi | Chief Operating Officer | Buy | 25,000.00 | 106,511.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000015/0001479290-20-000015-index.htm | ||
| 2020-09-30 | Abhay Joshi | COO, President, R&D | Buy | 17,500.00 | 119,332.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014240/0001628280-20-014240-index.htm | ||
| 2019-05-09 | Mark J Foley | Director | Buy | 4,500.00 | 13,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000054/0001479290-19-000054-index.htm | ||
| 2019-05-09 | Philip J. Vickers | Director | Buy | 4,500.00 | 13,650.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000062/0001479290-19-000062-index.htm | ||
| 2020-05-14 | Chris Nolet | Director | Buy | 6,000.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000068/0001479290-20-000068-index.htm | ||
| 2020-05-14 | Jill Beraud | Director | Buy | 6,000.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000071/0001479290-20-000071-index.htm | ||
| 2019-03-18 | L Daniel Browne | CEO and President | Sell | 11,613.00 | 15.51 | 180,067.69 | 151,193.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000038/0001479290-19-000038-index.htm |
| 2020-05-14 | Angus C. Russell | Director | Buy | 6,000.00 | 16,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000065/0001479290-20-000065-index.htm | ||
| 2020-05-14 | Julian S Gangolli | Director | Buy | 6,000.00 | 16,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000064/0001479290-20-000064-index.htm | ||
| 2020-05-14 | PHYLLIS GARDNER | Director | Buy | 6,000.00 | 16,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000067/0001479290-20-000067-index.htm | ||
| 2020-05-14 | ROBERT F BYRNES | Director | Buy | 6,000.00 | 16,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000066/0001479290-20-000066-index.htm | ||
| 2019-02-19 | L Daniel Browne | CEO and President | Sell | 5,446.00 | 17.68 | 96,285.28 | 168,943.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000020/0001479290-19-000020-index.htm |
| 2019-01-24 | L Daniel Browne | CEO and President | Buy | 35,000.00 | 177,543.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000018/0001479290-19-000018-index.htm | ||
| 2018-11-05 | Tobin Schilke | CFO | Buy | 18,000.00 | 18,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000112/0001479290-18-000112-index.htm | ||
| 2020-05-14 | Philip J. Vickers | Director | Buy | 6,000.00 | 19,650.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000069/0001479290-20-000069-index.htm | ||
| 2019-10-13 | Mark J Foley | CEO & President | Buy | 200,000.00 | 213,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000103/0001479290-19-000103-index.htm | ||
| 2019-01-24 | Tobin Schilke | CFO | Buy | 5,000.00 | 23,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000017/0001479290-19-000017-index.htm | ||
| 2019-01-24 | Caryn Gordon McDowell | SVP, GC & Secretary | Buy | 7,500.00 | 24,318.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000016/0001479290-19-000016-index.htm | ||
| 2020-02-18 | Dwight Moxie | SVP, GC & Secretary | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000028/0001479290-20-000028-index.htm | ||
| 2020-01-23 | Dustin S Sjuts | Chief Commercial Officer | Buy | 20,000.00 | 33,784.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000017/0001479290-20-000017-index.htm | ||
| 2020-09-30 | Dwight Moxie | SVP, GC & Secretary | Buy | 12,250.00 | 37,250.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014238/0001628280-20-014238-index.htm | ||
| 2020-01-23 | Tobin Schilke | CFO | Buy | 16,500.00 | 39,371.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000019/0001479290-20-000019-index.htm | ||
| 2018-11-20 | Cyril Allouche | Principal Accounting Officer | Sell | 491.00 | 20.66 | 10,144.06 | 4,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000121/0001479290-18-000121-index.htm |
| 2019-01-03 | Cyril Allouche | Principal Accounting Officer | Sell | 375.00 | 19.48 | 7,305.00 | 4,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000006/0001479290-19-000006-index.htm |
| 2019-01-22 | Cyril Allouche | Principal Accounting Officer | Sell | 625.00 | 17.77 | 11,106.25 | 4,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000010/0001479290-19-000010-index.htm |
| 2020-01-23 | Mark J Foley | CEO & President | Buy | 200,000.00 | 413,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000021/0001479290-20-000021-index.htm | ||
| 2019-01-22 | Cyril Allouche | Principal Accounting Officer | Buy | 625.00 | 13.35 | 8,343.75 | 4,625.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000010/0001479290-19-000010-index.htm |
| 2018-11-09 | Cyril Allouche | Principal Accounting Officer | Sell | 2,188.00 | 23.72 | 51,899.36 | 4,750.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000114/0001479290-18-000114-index.htm |
| 2020-09-30 | Dustin S Sjuts | Chief Commercial Officer | Buy | 17,500.00 | 51,564.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014246/0001628280-20-014246-index.htm | ||
| 2020-10-29 | Aubrey Rankin | President, Innovation & Tech | Sell | 33,119.00 | 26.15 | 865,949.25 | 543,803.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000093/0001479290-20-000093-index.htm |
| 2020-09-30 | Tobin Schilke | CFO | Buy | 15,750.00 | 55,308.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014242/0001628280-20-014242-index.htm | ||
| 2020-09-28 | Aubrey Rankin | President, Innovation & Tech | Sell | 33,119.00 | 26.18 | 867,055.42 | 576,922.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014083/0001628280-20-014083-index.htm |
| 2020-07-23 | Aubrey Rankin | President, Innovation & Tech | Buy | 610,041.00 | 610,041.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000082/0001479290-20-000082-index.htm | ||
| 2019-03-18 | Cyril Allouche | Principal Accounting Officer | Sell | 498.00 | 15.48 | 7,709.04 | 6,400.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000036/0001479290-19-000036-index.htm |
| 2020-07-23 | Aubrey Rankin | President, Innovation & Tech | Buy | 57,251.00 | 667,292.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929020000082/0001479290-20-000082-index.htm | ||
| 2018-11-09 | Cyril Allouche | Principal Accounting Officer | Buy | 2,188.00 | 13.35 | 29,209.80 | 6,938.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929018000114/0001479290-18-000114-index.htm |
| 2020-09-30 | Mark J Foley | CEO & President | Buy | 301,000.00 | 714,500.00 | https://www.sec.gov/Archives/edgar/data/1479290/000162828020014244/0001628280-20-014244-index.htm | ||
| 2019-01-24 | Cyril Allouche | Principal Accounting Officer | Buy | 3,150.00 | 7,150.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000015/0001479290-19-000015-index.htm | ||
| 2019-07-16 | Chris Nolet | Director | Buy | 9,000.00 | 9,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000083/0001479290-19-000083-index.htm | ||
| 2019-06-04 | Jill Beraud | Director | Buy | 9,000.00 | 9,000.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000069/0001479290-19-000069-index.htm | ||
| 2019-03-14 | Abhay Joshi | Chief Operating Officer | Buy | 666.00 | 4.20 | 2,797.20 | 90,443.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000034/0001479290-19-000034-index.htm |
| 2019-01-24 | Abhay Joshi | Chief Operating Officer | Buy | 15,750.00 | 91,287.00 | https://www.sec.gov/Archives/edgar/data/1479290/000147929019000014/0001479290-19-000014-index.htm |